Unless you have an intelligent meaningful post that provides insight to the many people that read this board, please refrain from posting. Everyone is responsible for doing their own due dilegence and making decisons regarding the purchase or sale of NBS shares.
Any thoughts on whether the current share price takes into account the acceptance of the Biologics License Application (BLA) for trastuzumab emtansine (T-DM1)? With Roche currently having 3 of the top 10 selling drugs, the approval of T-DM1 in the first half of 2013 will further strengthen their position within Oncology. Biosimiliar activity for Herceptin and Rituxan also appears to be muted at this time.